Eltanexor and Venetoclax

Phase Ib Study of Eltanexor and Venetoclax in Relapsed or Refractory Myelodysplastic Syndrome and Acute Myeloid Leukemia

More Information

Trial Status
Accepting patients
Trial Phase
Phase 1
Enrollment
60 patients (estimated)
Sponsors
Vanderbilt-Ingram Cancer Center
Collaborators
Karyopharm Therapeutics, National Cancer Institute (NCI)
Tags
Selective Inhibiton of Nuclear Export (SINE)
Trial Type
Treatment
Last Update
3 weeks ago
SparkCures ID
1913
NCT Identifier
NCT06399640

Real People. Real Support.

Need help connecting with this clinical trial? We're here to help!

Print this trial to share with your doctor.

We can help answer any questions and connect you (or your patient) with the study team.

Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.